COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,363 Articles (22,803 medRxiv, 8,560 bioRxiv)

Most recent first Previous |  Page 2153: Articles 21521-21530  | Next

Mathematical Analysis of COVID-19 Transmission Dynamics. A Case Study with Nigeria
Benedict, A. C., Emmanuel, O., Tenuche, B., William-Denteh, W.
10.1101/2020.10.20.20216473 — Posted: 2020-10-23
COVID-19 adaptive humoral immunity models: non-neutralizing versus antibody-disease enhancement scenarios
Danchin, A., Pagani-Azizi, O., TURINICI, G., Yahiaoui, G.
10.1101/2020.10.21.20216713 — Posted: 2020-10-23
SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020
Craigie, A., McGregor, R., Whitcombe, A., Carlton, L., Harte, D., Sutherland, M., Parry, M., Smit, E., McAuliffe, G., Ussher, J., Moreland, N., Jack, S., Upton, A.
10.1101/2020.10.20.20215616 — Posted: 2020-10-23
Covid-19 in children: is there any correlation with renal function and severity of the disease?
Sambas, D. R., Widiasta, A. A., Hilmanto, D., Sukandar, H., Sekarwana, N.
10.1101/2020.10.20.20216440 — Posted: 2020-10-23
Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2
Bojadzic, D., Alcazar, O., Chen, J., Buchwald, P.
10.1101/2020.10.22.351056 — Posted: 2020-10-22 Discussion: Onsite | Offsite
Broad transcriptional dysregulation of brain and choroid plexus cell types with COVID-19
Yang, A. C., Kern, F., Losada, P. M., Maat, C. A., Schmartz, G., Fehlmann, T., Schaum, N., Lee, D. P., Calcuttawala, K., Vest, R. T., Gate, D., Berdnik, D., McNerney, M. W., Channappa, D., Cobos, I., Ludwig, N., Schulz-Schaeffer, W. J., Keller, A., Wyss-Coray, T.
10.1101/2020.10.22.349415 — Posted: 2020-10-22
Distinct Phenotypes of SARS-CoV-2 Isolates Reveal Viral Traits Critical for Replication in Primary Human Respiratory Cells
Pohl, M. O., Busnadiego, I., Kufner, V., Schmutz, S., Zaheri, M., Abela, I., Trkola, A., Huber, M., Stertz, S., Hale, B. G.
10.1101/2020.10.22.350207 — Posted: 2020-10-22
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
Vitelli, A., Capone, S., Raggioli, A., Gentile, M., Battella, S., Lahm, A., Sommella, A., Contino, A. M., Urbanowicz, R. A., Scala, R., Barra, F., Leuzzi, A., Lilli, E., Miselli, G., Noto, A., Ferraiuolo, M., Talotta, F., Tsoleridis, T., Castilletti, C., Matusali, G., Colavita, F., Lapa, D., Meschi, S., Capobianchi, M., Soriani, M., Folgori, A., Ball, J. K., Colloca, S.
10.1101/2020.10.22.349951 — Posted: 2020-10-22
Analysis of SARS-CoV-2 ORF3a structure reveals chloride binding sites
Marquez-Miranda, V., Rojas, M., Duarte, Y., Diaz-Franulic, I., Holmgren, M., Cachau, R., Gonzalez-Nilo, F. D.
10.1101/2020.10.22.349522 — Posted: 2020-10-22
Databiology Lab CORONAHACK: Collection of Public COVID-19 Data
Caballero Perez, J., de Blas Perez, C., Leza Alvarez, F., Caballero Contreras, J. M.
10.1101/2020.10.22.328864 — Posted: 2020-10-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).